Media ReleasesImmutep

View All Immutep News

Immutep announces acceptance of abstract for SITC 2023

SYDNEY, AUSTRALIA – 3 October 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, today announces an abstract has been accepted for poster presentation at the Society
for Immunotherapy of Cancer (SITC) Annual Meeting 2023, taking place in San Diego, California and virtually from 1 to 5 November 2023.

For more information, download the attached PDF.

Download this document

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?